drugset
drugset / Trial / NCT03927443

A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension

NCT03927443 ↗

Phase 3 Withdrawn Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

To evaluate the efficacy of once daily dosing with SPARC's novel ophthalmic formulation of bimatoprost compared with Lumigan 0.01% in subjects with open-angle glaucoma or ocular hypertension.

Timeline

Start
2019-06-10
Primary completion
2019-07-08
Completion
2019-07-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bimatoprost Other / unclassified — —
Subject SDP-133 Unknown — —

Indications

ocular hypertension open-angle glaucoma